C8G

Summary

C8G (complement C8 gamma chain, HGNC:1354) is a protein-coding gene on chromosome 9q34.3, encoding Complement component C8 gamma chain (P07360). Component of the membrane attack complex (MAC), a multiprotein complex activated by the complement cascade, which inserts into a target cell membrane and forms a pore, leading to target cell membrane rupture and cell lysis.

The protein encoded by this gene belongs to the lipocalin family. It is one of the three subunits that constitutes complement component 8 (C8), which is composed of a disulfide-linked C8 alpha-gamma heterodimer and a non-covalently associated C8 beta chain. C8 participates in the formation of the membrane attack complex (MAC) on bacterial cell membranes. While subunits alpha and beta play a role in complement-mediated bacterial killing, the gamma subunit is not required for the bactericidal activity.

Source: NCBI Gene 733 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 71 total
• MANE Select transcript: NM_000606

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1354
Approved symbol	C8G
Name	complement C8 gamma chain
Location	9q34.3
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000176919
Ensembl biotype	protein_coding
OMIM	120930
Entrez	733

Gene structure

Transcript identifiers

Ensembl transcripts: 19 — 14 protein_coding, 2 retained_intron, 2 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

ENST00000371634, ENST00000465773, ENST00000484376, ENST00000647910, ENST00000649480, ENST00000649755, ENST00000870160, ENST00000870161, ENST00000870162, ENST00000870163, ENST00000870164, ENST00000870165, ENST00000870166, ENST00000870167, ENST00000870168, ENST00000870169, ENST00000870170, ENST00000870171, ENST00000870172

RefSeq mRNA: 1 — MANE Select: NM_000606 NM_000606

CCDS: CCDS7017

Canonical transcript exons

ENST00000371634 — 7 exons

Exon	Start	End
ENSE00000734162	136945243	136945458
ENSE00000734163	136945634	136945770
ENSE00000734168	136946085	136946192
ENSE00000734170	136946465	136946566
ENSE00001194952	136945929	136945999
ENSE00003686215	136946651	136946689
ENSE00003831539	136946768	136946975

Expression profiles

Bgee: expression breadth ubiquitous, 164 present calls, max score 99.51.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 2.2664 / max 845.4551, expressed in 59 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
99590	1.3284	48
99592	0.5861	34
99591	0.3292	31
99589	0.0226	9

Top tissues by expression

291 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right lobe of liver	UBERON:0001114	99.51	gold quality
liver	UBERON:0002107	96.45	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	91.26	gold quality
duodenum	UBERON:0002114	90.42	gold quality
jejunal mucosa	UBERON:0000399	86.48	gold quality
lower esophagus mucosa	UBERON:0035834	86.03	gold quality
hindlimb stylopod muscle	UBERON:0004252	85.11	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	84.11	gold quality
gastrocnemius	UBERON:0001388	83.81	gold quality
granulocyte	CL:0000094	82.31	gold quality
mucosa of transverse colon	UBERON:0004991	81.64	gold quality
muscle of leg	UBERON:0001383	81.00	gold quality
gall bladder	UBERON:0002110	80.91	gold quality
left testis	UBERON:0004533	79.04	gold quality
right testis	UBERON:0004534	78.93	gold quality
small intestine Peyer’s patch	UBERON:0003454	78.81	gold quality
small intestine	UBERON:0002108	78.56	gold quality
spleen	UBERON:0002106	77.01	gold quality
apex of heart	UBERON:0002098	75.74	gold quality
testis	UBERON:0000473	75.19	gold quality
transverse colon	UBERON:0001157	73.53	gold quality
heart left ventricle	UBERON:0002084	72.84	gold quality
muscle organ	UBERON:0001630	72.68	gold quality
right adrenal gland cortex	UBERON:0035827	72.43	gold quality
right lobe of thyroid gland	UBERON:0001119	72.34	gold quality
left adrenal gland cortex	UBERON:0035825	72.10	gold quality
left lobe of thyroid gland	UBERON:0001120	71.93	gold quality
right hemisphere of cerebellum	UBERON:0014890	71.93	gold quality
cardiac ventricle	UBERON:0002082	71.77	gold quality
adenohypophysis	UBERON:0002196	71.49	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-HCAD-9	yes	57.40
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

4 targeting C8G, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4649-3P	99.56	66.90	1783
HSA-MIR-6801-3P	98.04	64.64	805
HSA-MIR-6810-3P	97.96	64.57	1023
HSA-MIR-4329	97.68	66.26	1003

Literature-anchored findings (GeneRIF, showing 9)

• Binding of C8 gamma subunit to C8 beta is dependent on the thrombospondin type 1 module + low-density lipoprotein receptor class A module + membrane attack complex/perforin domain of C8 beta. (PMID:12220191)
• C8 alpha and C8 beta have correspondingly similar roles in MAC-mediated lysis of erythrocytes and bacterial killing. C8 gamma is not required for complement-mediated killing of Gram-negative bacteria. (PMID:12413696)
• results indicate that the principal binding site for C9 lies within the MACPF domain of C8alpha; they also suggest this site and the binding sites for C8beta and C8gamma are distinct (PMID:16618117)
• One can predict that the indel segment of C8alpha assumes a conformation that allows for multiple points of contact with C8gamma. (PMID:16935577)
• structure of a C8gamma.laurate complex revealed Y83 and Y131 can move to allow penetration of hydrocarbon chain of laurate into the lower cavity. A Y83W mutation blocked access but had no effect on the ability of C8gamma to enhance C8 cytolytic activity (PMID:17452033)
• Results describe the crystal structure of the human C8 alpha MACPF domain disulfide-linked to C8 gamma (alphaMACPF-gamma) at 2.15 A resolution. (PMID:18440555)
• C8gamma binds an indel peptide of C8alpha sequence and forms a non-covalent complex. (PMID:19048311)
• These data provide a detailed specification of co-occurring C8 proteoforms, including experimental evidence on N-glycosylation, C-mannosylation, and O-glycosylation. (PMID:29532326)
• Elevated complement component 8 gamma levels in astrocyte-derived exosomes are associated with cognitive impairment in obstructive sleep apnea patients without dementia. (PMID:36509166)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	c8g	ENSDARG00000032098
mus_musculus	C8g	ENSMUSG00000015083
rattus_norvegicus	C8g	ENSRNOG00000028701

Protein

Protein identifiers

Complement component C8 gamma chain — P07360 (reviewed: P07360)

All UniProt accessions (3): A0A3B3ITK5, A0A3B3ITY0, P07360

UniProt curated annotations — full annotation on UniProt →

Function. Component of the membrane attack complex (MAC), a multiprotein complex activated by the complement cascade, which inserts into a target cell membrane and forms a pore, leading to target cell membrane rupture and cell lysis. The MAC is initiated by proteolytic cleavage of C5 into complement C5b in response to the classical, alternative, lectin and GZMK complement pathways. The complement pathways consist in a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system. C8G, together with C8A and C8B, inserts into the target membrane, but does not form pores by itself. During MAC assembly, associates with C5b, C6 and C7 to form the C5b8 intermediate complex that inserts into the target membrane and traverses the bilayer increasing membrane rigidity.

Subunit / interactions. Heterotrimer of 3 chains: alpha (C8A), beta (C8B) and gamma (C8G); the alpha and gamma chains are disulfide bonded. Component of the membrane attack complex (MAC), composed of complement C5b, C6, C7, C8A, C8B, C8G and multiple copies of the pore-forming subunit C9.

Subcellular location. Secreted. Target cell membrane.

Activity regulation. Membrane attack complex (MAC) assembly is inhibited by CD59, thereby protecting self-cells from damage during complement activation. MAC assembly is also inhibited by clusterin (CLU) chaperones that inhibit polymerization of C9.

Similarity. Belongs to the calycin superfamily. Lipocalin family.

RefSeq proteins (1): NP_000597* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000566	Lipocln_cytosolic_FA-bd_dom	Domain
IPR002968	A1-microglobln	Family
IPR012674	Calycin	Homologous_superfamily
IPR022272	Lipocalin_CS	Conserved_site
IPR043245	C8G	Family

Pfam: PF00061

UniProt features (26 total): strand 11, helix 7, sequence variant 3, disulfide bond 2, signal peptide 1, chain 1, modified residue 1

Structure

Experimental structures (PDB)

15 structures.

PDB	Method	Resolution (Å)
1LF7	X-RAY DIFFRACTION	1.2
2OVA	X-RAY DIFFRACTION	1.5
2OVD	X-RAY DIFFRACTION	1.8
2QOS	X-RAY DIFFRACTION	1.81
1IW2	X-RAY DIFFRACTION	1.9
2OVE	X-RAY DIFFRACTION	2
2RD7	X-RAY DIFFRACTION	2.15
3OJY	X-RAY DIFFRACTION	2.51
8B0F	ELECTRON MICROSCOPY	3
7NYD	ELECTRON MICROSCOPY	3.27
8B0G	ELECTRON MICROSCOPY	3.3
8B0H	ELECTRON MICROSCOPY	3.3
7NYC	ELECTRON MICROSCOPY	3.54
6H03	ELECTRON MICROSCOPY	5.6
6H04	ELECTRON MICROSCOPY	5.6

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P07360-F1	90.06	0.78

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 21

Disulfide bonds (2): 60, 96–188

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-166665	Terminal pathway of complement
R-HSA-977606	Regulation of Complement cascade

MSigDB gene sets: 141 (showing top): REACTOME_INNATE_IMMUNE_SYSTEM, GNF2_GSTM1, GNF2_HPN, GOBP_LEUKOCYTE_MEDIATED_IMMUNITY, SHEPARD_BMYB_MORPHOLINO_DN, GOBP_B_CELL_MEDIATED_IMMUNITY, BROWNE_HCMV_INFECTION_48HR_DN, GOBP_REGULATION_OF_IMMUNE_RESPONSE, MODULE_75, GOBP_COMPLEMENT_ACTIVATION, GOBP_DEFENSE_RESPONSE_TO_OTHER_ORGANISM, GOBP_LYMPHOCYTE_MEDIATED_IMMUNITY, KEGG_PRION_DISEASES, GOBP_COMPLEMENT_ACTIVATION_ALTERNATIVE_PATHWAY, GNF2_LCAT

GO Biological Process (9): complement activation (GO:0006956), complement activation, alternative pathway (GO:0006957), complement activation, classical pathway (GO:0006958), killing of cells of another organism (GO:0031640), positive regulation of immune response (GO:0050778), transmembrane transport (GO:0055085), complement activation, GZMK pathway (GO:0160257), immune system process (GO:0002376), innate immune response (GO:0045087)

GO Molecular Function (2): retinol binding (GO:0019841), protein binding (GO:0005515)

GO Cellular Component (8): extracellular region (GO:0005576), membrane attack complex (GO:0005579), plasma membrane (GO:0005886), other organism cell membrane (GO:0044218), extracellular exosome (GO:0070062), blood microparticle (GO:0072562), membrane (GO:0016020), transmembrane transporter complex (GO:1902495)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Complement cascade	2

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
complement activation	3
cellular anatomical structure	3
innate immune response	2
immune response	2
immune effector process	1
activation of immune response	1
humoral immune response	1
protein activation cascade	1
humoral immune response mediated by circulating immunoglobulin	1
cell killing	1
disruption of cell in another organism	1
positive regulation of immune system process	1
positive regulation of response to stimulus	1
regulation of immune response	1
transport	1
cellular process	1
biological_process	1
defense response to symbiont	1
retinoid binding	1
vitamin binding	1
alcohol binding	1
binding	1
pore complex	1
plasma membrane protein complex	1
membrane	1
cell periphery	1
other organism part	1
extracellular vesicle	1
extracellular region	1
membrane protein complex	1
transporter complex	1

Protein interactions and networks

STRING

676 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
C8G	C8A	P07357	984
C8G	C8B	P07358	980
C8G	LCN1	P31025	794
C8G	PTGDS	P41222	719
C8G	PAEP	P09466	719
C8G	C1R	P00736	698
C8G	ORM1	P02763	618
C8G	C4BPB	P20851	583
C8G	C4BPA	P04003	573
C8G	C1S	P09871	562
C8G	HLA-DRB5	Q30154	551
C8G	C4A	P01028	541
C8G	LCN2	P30150	537
C8G	PGM1	P36871	507
C8G	C1QB	P02746	485

IntAct

15 interactions, top by confidence:

A	B	Type	Score
C8G	UBQLN2	psi-mi:“MI:0915”(physical association)	0.560
C5	C9	psi-mi:“MI:0915”(physical association)	0.550
S1PR2	PALM3	psi-mi:“MI:0914”(association)	0.530
	C8A	psi-mi:“MI:0915”(physical association)	0.400
	LECT2	psi-mi:“MI:0915”(physical association)	0.400
C8G	SEC24B	psi-mi:“MI:0914”(association)	0.350
AGPAT1	A2ML1	psi-mi:“MI:0914”(association)	0.350
RHBDD1	A2ML1	psi-mi:“MI:0914”(association)	0.350
	C5	psi-mi:“MI:0915”(physical association)	0.320
C8G	UBQLN2	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (14): C8G (Affinity Capture-MS), SEC24B (Affinity Capture-MS), TMEM2 (Affinity Capture-MS), SH3GL1 (Affinity Capture-MS), EDEM2 (Affinity Capture-MS), UBQLN2 (Two-hybrid), C8G (Reconstituted Complex), EDEM2 (Affinity Capture-MS), TMEM2 (Affinity Capture-MS), C8G (Affinity Capture-MS), SH3GL1 (Affinity Capture-MS), SEC24B (Affinity Capture-MS), C8G (Affinity Capture-MS), C8G (Affinity Capture-MS)

ESM2 similar proteins: B3EY83, B5X0G2, O02853, O09114, O18873, O97921, P02754, P02758, P04119, P07360, P07380, P09466, P11672, P13613, P19647, P21664, P21760, P22057, P30152, P31025, P33685, P33686, P33687, P33688, P41222, P53715, P62502, P62503, P67975, P67976, P80188, Q01584, Q28679, Q29095, Q29487, Q29562, Q5VSP4, Q6JVE6, Q6JVE9, Q6JVL5

Diamond homologs: P07360, Q28679, Q6UWW0, Q8VCG4, O02853, O09114, O97921, P22057, P41222, Q01584, Q29095, Q29487, Q29562, Q6ZST4, Q8WNM0, Q8WNM1, Q9I9P7, Q9TUI1, Q9XS65, Q9XSM0, P36992

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
C8G	“form complex”	“Membrane attack complex”	binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

71 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	44
Likely benign	12
Benign	3

Top pathogenic / likely-pathogenic (0)

SpliceAI

977 predictions. Top by Δscore:

Variant	Effect	Δscore
9:136945454:AGCAG:A	donor_loss	1.0000
9:136945455:GCAG:G	donor_gain	1.0000
9:136945455:GCAGG:G	donor_loss	1.0000
9:136945456:CAG:C	donor_loss	1.0000
9:136945457:AG:A	donor_loss	1.0000
9:136945458:GGTAG:G	donor_loss	1.0000
9:136946077:T:TA	acceptor_gain	1.0000
9:136946082:CAG:C	acceptor_loss	1.0000
9:136946083:A:AG	acceptor_gain	1.0000
9:136946083:AG:A	acceptor_loss	1.0000
9:136946084:G:GA	acceptor_gain	1.0000
9:136946084:GCCC:G	acceptor_gain	1.0000
9:136946190:ACGGT:A	donor_loss	1.0000
9:136946191:CGG:C	donor_loss	1.0000
9:136946192:GGTA:G	donor_loss	1.0000
9:136946193:G:GG	donor_gain	1.0000
9:136946193:GT:G	donor_loss	1.0000
9:136946194:T:G	donor_loss	1.0000
9:136946463:A:AG	acceptor_gain	1.0000
9:136946464:G:GG	acceptor_gain	1.0000
9:136946464:GCCC:G	acceptor_gain	1.0000
9:136946562:GTACG:G	donor_loss	1.0000
9:136946563:TACGG:T	donor_loss	1.0000
9:136946566:GGT:G	donor_loss	1.0000
9:136946567:G:GG	donor_gain	1.0000
9:136946567:GTGA:G	donor_loss	1.0000
9:136946568:T:A	donor_loss	1.0000
9:136945456:C:T	donor_gain	0.9900
9:136945460:T:G	donor_loss	0.9900
9:136945768:GCT:G	donor_gain	0.9900

AlphaMissense

1284 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
9:136945648:G:C	W51C	0.984
9:136945648:G:T	W51C	0.984
9:136945646:T:A	W51R	0.977
9:136945646:T:C	W51R	0.977
9:136945944:G:C	W97C	0.974
9:136945944:G:T	W97C	0.974
9:136946653:T:C	F187L	0.974
9:136946655:C:A	F187L	0.974
9:136946655:C:G	F187L	0.974
9:136946503:T:C	F165L	0.973
9:136946504:T:G	F165C	0.973
9:136946505:T:A	F165L	0.973
9:136946505:T:G	F165L	0.973
9:136946657:G:A	C188Y	0.969
9:136945658:G:C	A55P	0.967
9:136945939:T:A	C96S	0.965
9:136945940:G:C	C96S	0.965
9:136946656:T:A	C188S	0.964
9:136946657:G:C	C188S	0.964
9:136945940:G:A	C96Y	0.963
9:136946555:T:G	F182C	0.962
9:136946145:C:A	A136D	0.961
9:136946504:T:C	F165S	0.954
9:136945941:C:G	C96W	0.953
9:136945659:C:A	A55D	0.950
9:136945987:T:C	F112L	0.947
9:136945989:C:A	F112L	0.947
9:136945989:C:G	F112L	0.947
9:136945939:T:C	C96R	0.945
9:136946657:G:T	C188F	0.945

dbSNP variants (sampled 300 via entrez): RS1000090562 (9:136947040 C>T), RS1000096153 (9:136944601 G>A), RS1001147315 (9:136943759 C>A,G), RS1001178432 (9:136943836 A>G,T), RS1001268439 (9:136944754 G>C,T), RS1001896979 (9:136943263 A>C,T), RS1002303627 (9:136945307 C>A), RS1002930194 (9:136945990 C>A,G,T), RS1002945387 (9:136943812 C>G), RS1004106742 (9:136945856 C>A,T), RS1004545737 (9:136944946 T>A,C,G), RS1004793954 (9:136944768 C>G,T), RS1005083108 (9:136944876 C>G,T), RS1005451007 (9:136943244 A>C,G,T), RS1005497833 (9:136946717 G>A)

Disease associations

OMIM: gene MIM:120930 | disease phenotypes: MIM:300755

GenCC curated gene-disease

Mondo (1): immunodeficiency disease (MONDO:0021094)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST90013442_14	Keratoconus	1.000000e-11

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

38 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, increases expression	2
Benzo(a)pyrene	decreases expression	2
Tetrachlorodibenzodioxin	increases expression	2
Cyclosporine	decreases expression	2
Aflatoxin B1	affects expression, decreases expression	2
aristolochic acid I	increases expression	1
methyleugenol	decreases expression	1
pirinixic acid	affects binding, decreases expression, increases activity	1
decabromobiphenyl ether	decreases expression	1
tributyltin	affects binding, decreases reaction	1
tris(2-butoxyethyl) phosphate	affects expression	1
dibutyldichlorotin	affects binding, affects reaction, increases abundance	1
1-anilino-8-naphthalenesulfonate	affects binding	1
triphenyltin	affects binding, affects reaction, increases abundance, decreases reaction	1
11-(dansylamino)undecanoic acid	affects binding	1
di-n-butyltin	increases abundance, affects binding, affects reaction	1
diphenyltin	affects binding, affects reaction, increases abundance	1
di-n-butylphosphoric acid	affects expression	1
diphenyltin chloride	affects binding, affects reaction, increases abundance	1
triphenyllead chloride	affects binding, decreases reaction	1
abrine	increases expression	1
pentabrominated diphenyl ether 100	decreases expression	1
hexabrominated diphenyl ether 153	decreases expression	1
Rosiglitazone	decreases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Troglitazone	decreases expression	1
Acetaminophen	decreases expression	1
Cadmium	affects binding	1
Estradiol	decreases expression	1
Nickel	affects binding	1

Clinical trials (associated diseases)

247 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00001542	PHASE4	COMPLETED	Fluconazole Prophylaxis of Thrush in AIDS
NCT00144157	PHASE4	COMPLETED	Open Label Study of NVP+CBV Treatment in Women Who Have Received sdNVP for the pMTCT of HIV
NCT00162643	PHASE4	UNKNOWN	PI Vs. NNRTI Based Therapy for HIV Advanced Disease
NCT00273988	PHASE4	COMPLETED	Pharmacokinetic Study of Interaction Between Nevirapine and Methadone in HIV-1 Infected, Opioid-dependent Adults
NCT00981318	PHASE4	TERMINATED	Pilot Assessment of Lopinavir/Ritonavir and Maraviroc
NCT01086878	PHASE4	COMPLETED	Safety of Cotrimoxazole in HIV- and HAART-exposed Infants
NCT01090102	PHASE4	COMPLETED	Mesalamine to Reduce T Cell Activation in HIV Infection
NCT01147042	PHASE4	TERMINATED	Biochemical Response to Interferon-Gamma in Subjects With Specific Gene Mutation in Chronic Granulomatous Disease
NCT01230580	PHASE4	UNKNOWN	Protease Inhibitor Monotherapy Versus Ongoing Triple-therapy in the Long Term Management of HIV Infection (PIVOT)
NCT01465958	PHASE4	COMPLETED	Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency
NCT02274662	PHASE4	COMPLETED	Expanded Access Protocol Thymus Transplantation
NCT02348177	PHASE4	COMPLETED	Pharmacokinetics of Lopinavir/Ritonavir Superboosting in Infants and Young Children Co-infected With HIV and TB
NCT02396979	PHASE4	COMPLETED	Intervention of HIV, Drug Use and the Criminal Justice System in Malaysia
NCT02490956	PHASE4	UNKNOWN	Diagnostic Immunization With Rabies Vaccine in Patients With PID
NCT02503293	PHASE4	COMPLETED	A Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm® 165 mg/mL Administered With Two Different Delivery Devices: Injections Using Pump or Rapid Push
NCT02881437	PHASE4	COMPLETED	IgG Level in Primary Immunodeficiency Switching From Standard SCIG to Every Other Week HyQvia
NCT03033745	PHASE4	COMPLETED	Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)
NCT03677557	PHASE4	UNKNOWN	Safety, Tolerability, Patient Satisfaction and Cost of 16.5% Subcutaneous Immunoglobulin (Cutaquig®) Treatment
NCT04192487	PHASE4	COMPLETED	Effects of Crofelemer on the Gut Microbiome in Healthy Volunteers and in HIV+ Patients With Non-Infectious Diarrhea
NCT04566692	PHASE4	COMPLETED	A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary Immunodeficiency
NCT05493969	PHASE4	NOT_YET_RECRUITING	Efficacy and Tolerability of DTG Plus 3TC in HIV Infected Adults With Virologically Suppression and TDF Toxicity
NCT06576024	PHASE4	COMPLETED	Immunogenicity and Safety of Inactivated Hepatitis A Vaccine in HIV-infected People
NCT06634641	PHASE4	RECRUITING	Clozapine-related Immunodeficiency in Parkinsons Disease
NCT07076446	PHASE4	ACTIVE_NOT_RECRUITING	An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID)
NCT00000118	PHASE3	COMPLETED	Ganciclovir Implant Study for Cytomegalovirus Retinitis
NCT00000134	PHASE3	COMPLETED	Studies of the Ocular Complications of AIDS (SOCA)–Cytomegalovirus Retinitis Retreatment Trial (CRRT)
NCT00000590	PHASE3	COMPLETED	Anti-HIV Immunoglobulin (HIVIG) in Prevention of Maternal-Fetal HIV Transmission (Pediatric ACTG Protocol 185)
NCT00001267	PHASE3	COMPLETED	A Randomized Pilot Study for the Treatment of AIDS or AIDS Related Complex With an Alternating or Simultaneous Combination Regimen of AZT and 2’,3’-Dideoxyinosine
NCT00001646	PHASE3	COMPLETED	Voriconazole vs. Amphotericin B in the Treatment of Invasive Aspergillosis
NCT00144183	PHASE3	COMPLETED	A Study of Single Dose Nevirapine (NVP) Combined With Combivir® for the Prevention of Mother to Child Transmission (pMTCT) - Treatment Options Preservation Study (TOPS)
NCT00243568	PHASE3	WITHDRAWN	Vicriviroc, a CCR5 Inhibitor, Added to an Optimized Antiretroviral Therapy for Previously Treated HIV (VICTOR-E2) (Study P04285
NCT00278954	PHASE3	COMPLETED	Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases.
NCT00474370	PHASE3	COMPLETED	Vicriviroc in HIV-Treatment Experienced Subjects (Study P04889AM8)(COMPLETED)
NCT00478231	PHASE3	COMPLETED	Multicenter, Safety Study Of Maraviroc
NCT00523211	PHASE3	COMPLETED	Vicriviroc in HIV-Treatment Experienced Subjects (Study P04405AM5)
NCT00698334	PHASE3	COMPLETED	Efficacy of Thrice Weekly Directly Observed Treatment, Short-course (DOTS) in HIV-associated Tuberculosis
NCT00966160	PHASE3	COMPLETED	CD4 Cell Recovery in HIV-1 Patients Comparing 2 Treatment Regimes
NCT01363011	PHASE3	COMPLETED	Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
NCT01440569	PHASE3	COMPLETED	Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
NCT01475838	PHASE3	COMPLETED	Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients